AbbVie amps up 'armed antibody' deal with Seattle Genetics to the tune of $255M

Whatever AbbVie ($ABBV) learned in the first stages of its collaboration with Seattle Genetics ($SGEN) on antibody-drug conjugates must have seriously whetted the pharma company's appetite. AbbVie is now paying $25 million upfront and up to $255 million more in milestones for each new target they tackle in a greatly expanded partnership. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…